PROLIXIN Drug Patent Profile
✉ Email this page to a colleague
Which patents cover Prolixin, and when can generic versions of Prolixin launch?
Prolixin is a drug marketed by Apothecon and Bristol Myers Squibb and is included in five NDAs.
The generic ingredient in PROLIXIN is fluphenazine enanthate. There are nineteen drug master file entries for this compound. Additional details are available on the fluphenazine enanthate profile page.
AI Research Assistant
Questions you can ask:
- What is the 5 year forecast for PROLIXIN?
- What are the global sales for PROLIXIN?
- What is Average Wholesale Price for PROLIXIN?
Summary for PROLIXIN
| US Patents: | 0 |
| Applicants: | 2 |
| NDAs: | 5 |
| Raw Ingredient (Bulk) Api Vendors: | 128 |
| Clinical Trials: | 1 |
| Patent Applications: | 4,131 |
| DailyMed Link: | PROLIXIN at DailyMed |
Recent Clinical Trials for PROLIXIN
Identify potential brand extensions & 505(b)(2) entrants
| Sponsor | Phase |
|---|---|
| Canadian Institutes of Health Research (CIHR) | Phase 2 |
| Centre for Addiction and Mental Health | Phase 2 |
US Patents and Regulatory Information for PROLIXIN
| Applicant | Tradename | Generic Name | Dosage | NDA | Approval Date | TE | Type | RLD | RS | Patent No. | Patent Expiration | Product | Substance | Delist Req. | Exclusivity Expiration |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Apothecon | PROLIXIN | fluphenazine hydrochloride | CONCENTRATE;ORAL | 070533-001 | Nov 7, 1985 | DISCN | No | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Apothecon | PROLIXIN | fluphenazine hydrochloride | TABLET;ORAL | 011751-002 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| Apothecon | PROLIXIN | fluphenazine hydrochloride | TABLET;ORAL | 011751-004 | Approved Prior to Jan 1, 1982 | DISCN | Yes | No | ⤷ Sign Up | ⤷ Sign Up | ⤷ Sign Up | ||||
| >Applicant | >Tradename | >Generic Name | >Dosage | >NDA | >Approval Date | >TE | >Type | >RLD | >RS | >Patent No. | >Patent Expiration | >Product | >Substance | >Delist Req. | >Exclusivity Expiration |
